Compare DGICA & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICA | IRWD |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.2M | 663.6M |
| IPO Year | N/A | 2009 |
| Metric | DGICA | IRWD |
|---|---|---|
| Price | $16.21 | $4.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $19.00 | $7.67 |
| AVG Volume (30 Days) | 80.9K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $2.26 | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ $7.82 | $29.60 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $16.29 | $0.55 |
| 52 Week High | $21.06 | $5.78 |
| Indicator | DGICA | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 36.01 | 58.89 |
| Support Level | N/A | $3.80 |
| Resistance Level | $17.75 | $4.50 |
| Average True Range (ATR) | 0.39 | 0.25 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 20.47 | 79.49 |
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.